AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01601015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
Study NCT03595462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Snack
Description: The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
Study NCT01889407 — intervention group
Intervention type: DRUG
Intervention: Idarubicin
Description: 8 mg/m2, iv drip on days 1-3
Study NCT04207528 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Writing
Description: After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
Study NCT04207528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing
Description: After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
Study NCT03519139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual dietary counselling
Description: individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
Study NCT01637480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic manipulation
Description: High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
Study NCT01637480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation
Description: High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
Study NCT02025660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mw, 0.3ml x three days sc
Study NCT02025660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00694408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl prednisolone, hydrocortisone, prednisolone
Description: Will be specific dependant on weight of patients
Study NCT00694408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No steroids
Description: Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
Study NCT01318369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namisol
Description: Single dose delta-9-tetrahydrocannabinol
Study NCT01318369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
Study NCT02975856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Table Red Wine
Study NCT02975856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Young Port Red Wine
Study NCT05589753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure.
Study NCT05589753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 6 days. On the final 4 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
Study NCT01447147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: CCX140-B capsules once daily (Group C)
Study NCT02296359 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza Vaccination
Description: The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
Study NCT02935374 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Macrolide
Description: The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
Study NCT04569071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinovation Laser Ablation System
Description: In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.
Study NCT02093351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
Study NCT02093351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
Study NCT02093351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg Anastrozole once daily Day 10 - Day 24
Study NCT02093351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg Letrozole once daily Day 10 - Day 43
Study NCT02093351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling
Description: Blood sampling over 12-24 hour period for pharmacokinetic analysis
Study NCT01454063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Study NCT01454063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Study NCT01330524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin and Triamcinolone
Description: 1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
Study NCT01330524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2mg placebo
Study NCT05125627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)
Description: Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
Study NCT05125627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
Description: Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
Study NCT03149380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based education
Description: The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
Study NCT03149380 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Web-based education
Description: The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
Study NCT03123562 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Transplantation of Autologous Bone Marrow Mononuclear Cells
Study NCT02163447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly dihydroartemisinin-piperaquine (DP) for infants
Study NCT02163447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-monthly dihydroartemisinin-piperaquine (DP) for infants
Study NCT03654053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo taken once nightly at bed time.
Study NCT01601015 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position.
Study NCT02602431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-oral laser irradiation
Description: Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
Study NCT02602431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-oral laser irradiation
Description: Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
Study NCT02602431 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Extra-oral placebo
Description: Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
Study NCT02602431 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intra-oral Placebo
Description: Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
Study NCT00642616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin
Description: Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
Study NCT00642616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
Study NCT01359540 — intervention group
Intervention type: DEVICE
Intervention: OMNI Apex Modular™ Hip Device
Study NCT01359540 — intervention group
Intervention type: DEVICE
Intervention: OMNI Apex ARC™ Hip Device
Study NCT03389334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: The techniques include myofascial release and manual active and passive stretching with the intention to lengthen overly contracted or shortened tissue, increase range of motion, and restore any malpositioning of structural landmarks as defined by its contralateral counterpart. By addressing the symptoms of the somatic dysfunction, you will in turn reduce the overall perceived pain in the body caused in these related tissues. The duration of each massage treatment session will be 45 minutes long and therapists will use a timer to ensure all subjects receive the same length of treatment. Patients will continue to receive treatment from the same therapist to maintain consistency of results.
Study NCT02345161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple FF/UMEC/VI
Description: The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
Study NCT02345161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match FF/UMEC/VI
Description: The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
Study NCT02345161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol
Description: The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
Study NCT01782053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Picture warning
Description: Warning contains picture proposed for each text statement by FDA
Study NCT01782053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Study NCT02345161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Budesonide/Formoterol combination
Description: The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
Study NCT02937948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptative treatment plan
Description: Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder.
Study NCT02937948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External radiotherapy
Description: At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
Study NCT03654053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40mg taken once nightly at bed time.
Study NCT03426657 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab + RT
Description: Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
Study NCT00663234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
Study NCT03821675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation - Active
Description: Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
Study NCT03821675 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrical Stimulation - Sham
Description: Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
Study NCT00594035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Sealant System
Study NCT02345161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
Study NCT00594035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care: devices intended to provide a watertight closure
Study NCT01206387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone Spray 0.25%
Description: Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
Study NCT01206387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: Placebo administered to affected area twice a day for 28 days
Study NCT02873585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stationary intraoral tomosynthesis
Description: Bitewing radiographs using a stationary intraoral tomosynthesis unit
Study NCT02873585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard conventional bitewing radiography
Description: Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
Study NCT03269552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT04201522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normocapnic hyperpnoea intervention
Description: Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at 60% of the peak of minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
Study NCT04201522 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at rest's minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
Study NCT03940573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse Insert
Description: Rectal Control System.
Study NCT03269552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03269552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04174014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvre
Description: PEEP increment and decrement
Study NCT00588952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine and Placebo
Description: Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes
Study NCT04134858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The nurse-led health coaching program
Description: The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
Study NCT01668433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regimens (Primaquine, Methylene blue)
Description: Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
Study NCT01668433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimens (Primaquine, Methylene blue)
Description: Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
Study NCT00806624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b tablets
Description: DU-176b tablets taken once daily for up to 3 months
Study NCT00806624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin tablets
Description: Warfarin tablets taken once daily for up to 3 months
Study NCT01403389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: 1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
Study NCT01403389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
Study NCT01918293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART ARM
Description: The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.